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Abstract
Background: Apoptosis inhibitor of macrophages (AIM) was initially identified as an apoptosis inhibitor that supports the
survival of macrophages against various apoptosis-inducing stimuli, and AIM produced by macrophages may contribute
to the pathogenesis of inflammatory bowel diseases (IBDs). However, there have been no reports on the kinetics of AIM
in IBD and the impact of AIM on the pathogenesis of IBD. In this study, we aimed to investigate the diagnostic utility of
levels of AIM and their correlation with the activity of Crohn’s disease (CD) and IBD.
Methods: We used an enzyme-linked immunosorbent assay (ELISA) to examine AIM serum levels in 16 healthy subjects
and 90 patients with inflammatory bowel diseases, namely 39 with CD and 51 with ulcerative colitis (UC), as well as 17
patients with Behcet’s disease (BD) as intestinal disease controls. We compared serum AIM levels among groups and
examined whether there were correlations between serum AIM levels and disease activity and type. We also performed
immunohistochemical staining of AIM in intestinal tissues of patients with CD.
Results: Serum AIM levels were significantly higher in patients with CD than in patients with UC, BD, and controls (3.27 ±
2.14, 1.88 ± 1.43, 2.34 ± 1.37, and 2.13 ± 0.64 μg/ml, respectively; P < 0.01). There was no difference in serum AIM levels
before and after treatment in patients with CD. However, in these patients the diagnostic rate using AIM was better than
that based on anti-Saccharomyces cerevisiae antibodies. AIM was expressed in macrophages that were positive for CD14,
CD16, or both in the intestinal tissues of patients with CD.
Conclusions: AIM is a novel biomarker of CD that can distinguish CD from UC or BD. It is suggested that AIM may
contribute to intestinal inflammation by inhibiting the apoptosis of macrophages.
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Background
Inflammatory bowel diseases (IBDs), including Crohn’s dis-
ease (CD) and ulcerative colitis (UC), are chronic intestinal
disorders of unclear etiology [1]. The incidence of both
conditions is increasing globally, and it is suggested that
disease risk correlates with environmental changes [2]. Al-
though the etiology of IBD remains unknown, it is thought
to be strongly associated with the microbiome and the
environmental factors that influence the microbiome [3].
Intestinal macrophages influence local homeostasis and
help maintain a balance between commensal microbiota
and the host. Additionally, intestinal macrophages play es-
sential roles in intestinal inflammation. As a result, disor-
ders of intestinal macrophages may cause unbalanced
immune responses to commensal bacteria and lead to the
development of chronic intestinal inflammation [4]. These
macrophages play an important role in the pathogenesis of
IBDs such as CD [5, 6].
The diagnosis of IBD is based on endoscopic, histologic
and radiologic criteria. Disease activity in IBD is determined
using both direct and non-invasive laboratory markers.
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However, endoscopy is still the gold standard diagnostic
test, even though it is invasive [7, 8]. Several serological
markers, such as C-reactive protein (CRP), as well as
erythrocyte sedimentation rate (ESR) and platelet count or
fecal calprotectin have been reported to be useful for diag-
nosing IBD and assessing disease activity and response to
therapy [9–15]. An ideal marker for IBD would have high
disease specificity, predictive ability for relapse of disease
activity, and is cheap and noninvasive [16]. Currently, sev-
eral serologic markers have been suggested as useful for the
diagnosis, differentiation, and better comprehension of the
pathogenesis of IBD [17–20]. Among them, anti-Saccharo-
myces cerevisiae antibodies (ASCA) and perinuclear anti-
neutrophil cytoplasmic antibodies have been reported to be
useful serum biomarkers for CD and UC, respectively [21].
ASCA has a low positivity rate of between 38.3 and 45.6%
Table 1 Clinical characteristics
CD UC BD Control P value
Number of patients 39 51 17 16
Gender
Male 20 27 9 14 0.070
Female 19 24 8 2
Mean age (±SD), yr 32.4 ± 14.5 45.2 ± 22.8 47.5 ± 17.6 32.4 ± 3.8 0.014



















5-ASA 25 43 13
Steroid 2 18 6
Azathioprine 0 5 0
Infliximab 5 0 0
Adalimumab 1 0 0
GMA/LCAP 1 6 1
AIM (μg/ml)
Average (±SD) 3.3 ± 2.1 1.9 ± 1.4 2.3 ± 1.4 2.1 ± 0.6 <0.001
WBC (±SD), x102/μl 6.7 ± 2.6 8.4 ± 3.9 7.3 ± 2.8 – 0.055
CRP (±SD), mg/dl 2.5 ± 3.5 3.6 ± 5.8 2.7 ± 4.0 – 0.929
IgM (±SD), mg/dl 141.5 ± 124.3 118.0 ± 77.9 118.0 ± 64.9 – 0.275
Abbreviations: GMA/LCAP granulocyte and monocyte adsorptive apheresis / leukocytapheresis, WBC White blood cell, CRP C-reactive protein, IgM
Immunoglobulin M
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in CD patients, but there is low sensitivity and specificity
for the diagnosis of CD [22, 23]. A definite diagnosis is ne-
cessary for properly choosing clinical follow-up and suitable
therapies. However, some IBD cases share several endo-
scopic and histologic features with both CD and UC; these
are defined as indeterminate colitis [24]. Therefore there is
still a need in clinical settings for IBD markers with high
sensitivity and specificity.
Apoptosis inhibitor of macrophages (AIM) was initially
identified as an apoptosis inhibitor that supports the sur-
vival of macrophages against various apoptosis-inducing
stimuli [25]. AIM is produced exclusively by tissue macro-
phages and itself influences these cells [26]. Higher blood
levels of AIM are associated with autoimmune disease,
but only in obese individuals. Arai et al. implicated blood
AIM as a biomarker for obesity-associated autoimmune
disease in humans [27]. Disorders of intestinal macro-
phages may lead to the development of chronic intestinal
inflammation, and AIM produced by the macrophage may
contribute to the pathogenesis of IBDs such as CD [4–6].
However, there have been no reports on the kinetics of
AIM in IBD and the impact of AIM on the pathogenesis
of IBD. In this study, we aimed to investigate AIM kinetics
in the blood and tissues of patients with IBD, and exam-
ined the utility of AIM as a biomarker of IBD. We then
determined whether blood levels of AIM were associated
with clinical features such as disease activity and type.
Methods
Patients
This study enrolled 90 IBD patients, 39 of whom were
diagnosed with CD and 51 with UC (Table 1). Seventeen
patients with intestinal Behcet’s disease (BD) were used
as intestinal disease controls. There were also 16 healthy
individuals in the control group. Of the 39 patients with
CD, 20 were men and 19 were women, with a mean age
of onset of 32.4 years (range, 8–79 years). Of the 51 pa-
tients with UC, 27 were men and 24 were women, with
a mean age of onset of 45.2 years (range, 8–79 years). Of
the 17 patients with BD, 9 were men and 8 were women,
with a mean age of onset of 47.5 years (range, 8–79
years). The mean age of healthy controls was 32.4 years
(range, 8–79 years). All IBD patients were diagnosed
using established endoscopic, radiological, histological,
and clinical criteria. The clinical characteristics of sub-
jects are summarized in Table 1. Twelve patients with
CD had high disease activities, defined as a Crohn’s Dis-
ease Activity Index (CDAI) score of 150 or greater. Clin-
ically, CD occurred as the ileal type in 9 patients, the
ileocecal type in 25 patients, the colonic type in 4
patients, and unknown type in 1 patient. Twenty-two
patients with UC were in the remission phase while 29
were in the active phase. The active phase was defined
as a Lichtiger’s clinical activity index (CAI) score greater
than or equal to 6. All patients with BD had high disease
activity based on clinical symptoms. Blood samples were
collected with informed consent. The patients were
treated at Kagoshima University Hospital from January
2007 to December 2013. The sera and intestinal tissue
specimens of patients were stored at −80° until analysis.
Excised intestinal tract tissue was stored after formalin
fixation. Serum analysis was performed using the re-
agents and kits mentioned below. The ethics committee
at Kagoshima University Hospital approved the study
protocol, and written informed consent was obtained
from each participant.
ELISA measurements of serum AIM and ASCA levels
We measured the serum AIM concentrations in 90 pa-
tients with IBD, 17 with BD, and 16 heathy individuals as
described above. AIM levels were determined using ELISA
kits from Trans Genic Inc. (Kumamoto, Japan). For com-
parison, we measured ASCA immunoglobulin G (IgG) in
patients with CD and UC, but not those with BD. ASCA
IgG concentrations were measured using ELISA kits from
Genesis Diagnostics (Cambridgeshire, UK). Briefly, serum
samples diluted at 1:100 were added to wells and incu-
bated for one hour at room temperature, and then each
well was washed three times with phosphate-buffered sa-
line. Horseradish peroxidase-conjugated anti-human IgG
was added to each well.
Fig. 1 Comparison of serum AIM levels in patients with Crohn’s disease
(CD), ulcerative colitis (UC), intestinal Behcet’s disease (BD), and healthy
volunteers (HV). Serum AIM levels in the patients with CD were
significantly higher than those in the other groups
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Immunohistological analysis
Small intestinal tissues from patients with active-phase
CD were obtained after ileocecal resection due to in-
tractability to medical treatment. Briefly, tissue samples
were fixed with 10% buffered formalin, embedded in
paraffin, and stained with hematoxylin and eosin. For
immunofluorescence analysis, paraffin sections were in-
cubated with anti-human AIM (AnaSpec, Fremont, CA,
USA), anti-human CD14 (Abcam plc, Cambridge, UK),
and anti-human CD16 (AbD Serotec, Oxford, UK),
followed by imaging under a fluorescence microscope.
Statistical analysis
Results are expressed as means ± standard deviation
(SD). P values less than 0.05 were considered statistically
significant. Statistical analyses were performed using the
Chi-square or Mann-Whitney U test, as appropriate.
Correlation coefficients were calculated by Spearman’s
rank correlation analysis. The discriminatory power for
each putative marker was described using the receiver
operating characteristics (ROC) area under the curve
(AUC) (ROC-AUC). Cut-off values were obtained from
ROC-AUC analysis. Statistical analysis was conducted
using PASW Statistics 18 (SPSS Inc., Chicago, IL, USA).
Results
Serum AIM levels and clinical characteristics in patients
with IBD and healthy controls
The clinical characteristics of subjects are summarized
in Table 1. The serum AIM concentrations in 39 pa-
tients with CD, 51 with UC, 17 with BD, and 16 healthy
controls were 3.27 ± 2.14, 1.88 ± 1.43, 2.34 ± 1.37, and
Fig. 2 Correlation among serum AIM levels and various parameters and inflammatory markers in patients with CD. IgM were positively correlated
with serum AIM levels. There were no statistically significant differences between AIM levels and other markers
Ono et al. BMC Gastroenterology  (2017) 17:40 Page 4 of 9
2.13 ± 0.64 μg/ml, respectively (Table 1). Serum AIM
levels in patients with CD were significantly higher than
those in patients with UC and BD and those in healthy
controls (p < 0.01 for the other groups); there was no sig-
nificant difference among the latter 3 groups. Figure 1
shows the serum AIM concentration in each group.
There was no significant difference between white blood
cell (WBC) counts or levels of AIM, IgM, or CRP among
the groups with CD, UC, and BD.
Association between serum AIM levels and other
laboratory data in patients with CD
We found that serum AIM levels were positively corre-
lated with IgM in patients with CD. In contrast, no IBD
patients showed significant associations between serum
AIM levels and inflammatory markers such as WBC
counts, CRP levels, age, disease duration, body mass
index, or CDAI scores (Fig. 2). In addition, there was no
association between AIM levels and disease entities
(Fig. 3). We also compared serum AIM levels before and
after induction therapy in 14 patients with CD, 9 of
whom had successfully entered the remission phase and
5 of whom were in the chronic active phase (Table 2).
None of these patients showed an association between
serum AIM levels and disease activity (Fig. 3).
Diagnostic utility of serum AIM and ASCA levels in CD
We next compared serum ASCA-IgG levels to evaluate
the utility of AIM for distinguishing between CD and UC.
The means ± SD of ASCA were 955.7 ± 382.6, 270.4 ± 205,
and 268.5 ± 278.3 U/ml in patients with CD, patients with
UC, and healthy controls, respectively. Serum ASCA
levels in the CD patients were significantly higher than
those in patients with UC and healthy controls (p < 0.01
for the other groups; Fig. 4).
Although, there was association between AIM levels
and serum ASCA levels (Fig. 2), the ROC-AUCs of AIM
and ASCA were 0.79 and 0.73, respectively. ROC-AUC
Fig. 3 a. Comparison of serum AIM levels in patients with CD, UC, or
intestinal BD. b. Comparison of serum AIM concentrations before and
after treatment in patients with CD in active (n= 5) and remission (n= 9)
stages. Induction treatments comprised prednisolone, tacrolimus, 5-ASA,
cyclosporine, azathioprine, and/or leukocytapheresis in all 14 patients
with CD. Nine patients successfully entered remission while five patients
remained in the active stage after induction treatment. There was no
significant difference in AIM levels between the two groups. Each symbol
indicates one patient
Table 2 Clinical characteristics of CD patients in remission or
active phase
Remission Active P value
Number of patients 9 5
Gender
Male 3 2 0.969
Female 6 3
Mean age (±SD), yr 28.8 ± 16.8 24.0 ± 8.7 0.898
BMI (±SD), kg/m2 18.6 ± 3.1 20.2 ± 6.3 0.898
CDAI
≥ 150 5 4 0.658
< 150 4 1
Disease location
Ileal type 3 0 0.167
Ileocolonic type 6 4










Average (±SD) 3.8 ± 3.7 3.3 ± 2.1 0.797
After treatment
Average (±SD) 4.4 ± 5.3 3.1 ± 2.7 0.699
asome treatments overlapped
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analysis revealed that a serum AIM level of 1.88 μg/ml
was the optimal cut-off value to differentiate between CD
and UC, with 76.3% sensitivity and 76.5% specificity, a
positive predictive value of 65.9%, a negative predictive
value of 80.6, and 72.5% accuracy. With a cut-off value of
320 U/ml, ASCA had a sensitivity of 60.5%, a specificity of
72.5%, a positive predictive value of 62.2%, a negative pre-
dictive value of 71.1, and 67.4% accuracy (Fig. 5). Thus,
the diagnostic utility of AIM is non-inferior to ASCA for
the differential diagnosis of UC and CD.
AIM expression in intestinal macrophages
Histological evaluation was performed to localize AIM in
tissue sections from patients with CD who had undergone
intestinal resection due to severe intestinal inflammation.
The small intestinal tissue of patients with CD showed
invasion of inflammatory cells into the submucosa
(hematoxylin and eosin staining). Immunostaining showed
that AIM was strongly expressed in intestinal mononuclear
but not epithelial cells in patients with CD (Fig. 6). Double
immunostaining, performed to identify cells expressing
AIM, showed that a number of AIM-positive mononuclear
cells were stained by antibodies to CD14, CD16, or both,
and AIM was dominantly expressed in CD16-positive cells.
These results demonstrate that AIM is expressed in active
macrophages located in the intestinal mucosa (Fig. 6).
Discussion
This study is the first to measure serum AIM concentra-
tions in patients with IBD. We showed that serum AIM
levels were higher in CD patients than in those with UC
or intestinal BD or in healthy controls. In addition, we
confirmed that AIM was expressed in CD14- and CD16-
positive macrophages in intestinal tissue. AIM, a member
of the scavenger receptor cysteine-rich superfamily, is ini-
tially identified as an apoptosis inhibitor that supports the
survival of tissue macrophages against different types of
pro-apoptotic stimuli [28, 29]. We speculate that AIM,
produced by resident macrophages in intestinal tissue, con-
tributes to intestinal inflammation, and active macrophage-
derived AIM in the intestines results in elevated serum
AIM levels.
Intestinal macrophages play important roles in local
homeostasis and mucosal inflammation. Unique macro-
phages in normal colonic mucosa generally attenuate im-
mune functions and induce protective immunity. As a
result, intestinal macrophages contribute significantly to
the pathogenesis of CD [5, 6]. Colonic macrophages show
higher expression of CD14 and CD16 in patients with IBD
than in healthy controls, indicating additional macrophage
populations in the inflamed mucosa [5]. Infiltrating macro-
phages contribute to the initiation and sustention of the
mucosal inflammation that is characteristic of human IBD.
In addition, peripheral blood monocytes expressing CD16
were previously identified as a major proinflammatory cell
population, producing cytokines such as tumor necrosis
factor-α (TNF-α), interleukin (IL)-1, and IL-12 [30, 31].
Koch et al. reported that CD16-positive peripheral blood
Fig. 4 Comparison of serum ASCA levels between patients with
Crohn’s disease (CD), ulcerative colitis (UC), and healthy volunteers
(HV). Serum AIM levels were significantly higher in patients with CD
than in the other groups
Fig. 5 Receiver operating characteristic (ROC) curves of apoptosis
inhibitor of macrophage (AIM) and anti-Saccharomyces cerevisiae
antibodies (ASCA) for the diagnosis of Crohn’s disease (CD). The ROC
curves for AIM and ASCA were obtained by plotting sensitivity versus
1-specificity. Sensitivity and specificity were each calculated using
ELISA. AIM had a sensitivity of 68.2%, a specificity of 80.6%, a positive
predictive value (PPV) of 65.9%, a negative predictive value (NPV) of
80.6%, and an accuracy of 72.5% for distinguishing CD from ulcerative
colitis, while the corresponding values for ASCA were 60.5, 72.5, 62.2,
71.1, and 67.4%, respectively
Ono et al. BMC Gastroenterology  (2017) 17:40 Page 6 of 9
monocytes were significantly increased in active CD, par-
ticularly in patients with colonic involvement. Thus,
CD14- and CD16-positive monocytes and macrophages,
which are major contributors to the inflammatory infiltrate
in the lamina propria, constitute a pivotal proinflammatory
cell population in CD due to their production of large
amounts of inflammatory cytokines such as IL-12, IL-23,
and TNF-α [32–34].
Given the above, a significant reduction in peripheral
CD14- and CD16-positive monocytes by leukocyte
apheresis/adsorption and corticosteroids should improve
intestinal inflammation [34, 35]. Azathioprine was also
shown to inhibit the proliferation of CD16-positive cells
in blood and lamina, resulting in the improvement of
enterocolitis. In addition, infliximab has a reduced effect
if there are no CD14-positive cells in the lamina propria.
These result show that AIM derived from CD14- or
CD16-positive cells inhibits the apoptosis of intestinal
macrophages by autocrine or paracrine mechanisms,
and may thereby result in the sustentation of intestinal
inflammation.
Recent clinical studies have reported high serum AIM
levels in patients with liver fibrosis and chronic hepatitis
C, [36] liver damage in patients with hepatocellular car-
cinoma, [37] and obesity-associated autoimmune disease
in humans [38]. We confirmed that serum levels of
AIM, which is actively secreted by active macrophage in
the intestine, were found at higher levels in patients with
CD than in patients with UC or intestinal BD or in
healthy controls. Since AIM levels were high only in the
patients with CD and not in those with UC or intestinal
BD, the evaluation of AIM levels may be helpful as an
CD16AIM







Fig. 6 Immunohistochemical staining of small intestine samples from patients with active CD. AIM expression is noted in submucosal mononuclear cells
positive for CD14 (a) or CD16 (b). Some mononuclear cells were positive for CD14, CD16, and AIM antibodies (c; arrow). Microscopic magnification is × 400
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auxiliary method of discriminating between CD and
other chronic intestinal diseases. Although serum AIM
levels were not associated with disease activity or clinical
characteristics in CD, and there were no changes in AIM
levels before and after treatment, increases of AIM are
likely to be related to the pathogenesis of CD, namely in
the sustentation of inflammation due to the inhibition of
macrophage apoptosis.
ASCA, a major serum marker, has been reported as
a screening tool for CD. In this study, ROC analysis
showed that AIM had better sensitivity and specificity
than ASCA for the screening of CD and intestinal in-
flammation disease. It is a well-known fact that ASCA
is a less useful test in Asian than Caucasian popula-
tions [39]. It is possible that AIM can be used to
screen for CD in patients from the Asian general
population who have undiagnosed gastrointestinal
symptoms.
The sequential assessments of AIM levels in the same
CD patients before and after treatment showed no
changes in this study. While this analysis comprised only
a small number of patients, serum AIM levels do not ap-
pear to be associated with disease activity in CD. However
it is suggested that the upregulation of AIM may reflect
the sustention of chronic inflammation in CD caused by
the inhibition of apoptosis of active intestinal macro-
phages, and correlate with disease susceptibility in CD.
It has long been recognized that hypertrophied mesen-
teric adipose tissues surround the intestinal mesentery
in CD [40]. Although TNF-α derived from these mesen-
teric adipose tissues induces intestinal inflammation, the
cause and pathology of the CD-specific mesenteric adi-
pose tissue accession have not been clearly elucidated.
AIM is incorporated into adipocytes via CD36-mediated
endocytosis, and subsequently induces lipolysis. There-
fore it may play a role in inflammatory macrophage re-
cruitment and induce TNF-α in mesenteric adipose
tissues in CD [26–28, 41, 42]. AIM may influence the
pathogenesis of CD not only by inhibiting the apoptosis
of active intestinal macrophages, but also by enhancing
the expression of TNF-α in these mesenteric adipose
tissues.
There are several limitations to this study. First, it used
a single-center design and enrolled a small number of
patients. Therefore we should examine a larger sample
in the near future. Second, AIM was expressed by active
macrophages, although there was no association be-
tween serum AIM levels and CD activity. The inductive
activity of AIM expression in macrophages is still un-
clear in the inflamed intestines of patients with CD. We
plan to investigate this issue by analyzing the function of
the AIM gene using gene-modified mice, as there have
been no reports of colitis mouse models in AIM knock-
out mice.
Conclusions
AIM is a novel biomarker of CD that can distinguish CD
from UC or BD. It is suggested that AIM may contribute
to intestinal inflammation by inhibiting the apoptosis of
macrophages.
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